Cargando…

Does ruxolitinib really prolong survival in individuals with myelofibrosis? The never-ending story

Detalles Bibliográficos
Autores principales:	Barosi, Giovanni, Gale, Robert Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006303/ https://www.ncbi.nlm.nih.gov/pubmed/35240682 http://dx.doi.org/10.1182/bloodadvances.2022007230

Ejemplares similares

Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis
por: Barosi, Giovanni, et al.
Publicado: (2015)

Saturated fat –a never ending story?
por: Svendsen, Karianne, et al.
Publicado: (2017)

Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013)

RR6 prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real-life cohort
por: Scalzulli, Emilia, et al.
Publicado: (2022)

Commentary: Papillary muscle relocation for secondary mitral regurgitation: A never-ending story
por: Murana, Giacomo, et al.
Publicado: (2021)

Commentary: The never-ending story of COVID-19: Accustoming to the new abnormal in glaucoma practice
por: Ramesh, Prasanna V, et al.
Publicado: (2023)

Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016)

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
por: Manduzio, Palma
Publicado: (2017)

Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing
por: Mesa, Ruben A, et al.
Publicado: (2013)

Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis
por: Verstovsek, S, et al.
Publicado: (2016)

Ruxolitinib therapy and telomere length in myelofibrosis
por: Caocci, G, et al.
Publicado: (2016)

Management of myelofibrosis after ruxolitinib failure
por: Harrison, Claire N, et al.
Publicado: (2020)

Sarin: a never-ending story
por: Bolt, Hermann M.
Publicado: (2022)

Doping in Sports, a Never-Ending Story?
por: Vlad, Robert Alexandru, et al.
Publicado: (2018)

Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms. Challenges and perspectives
por: Barosi, Giovanni, et al.
Publicado: (2023)

Ruxolitinib for the treatment of myelofibrosis: its clinical potential
por: Ostojic, Alen, et al.
Publicado: (2012)

Definition and management of ruxolitinib treatment failure in myelofibrosis
por: Pardanani, A, et al.
Publicado: (2014)

Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis
por: Claudiani, Simone, et al.
Publicado: (2021)

Mystic Acetaldehyde: The Never-Ending Story on Alcoholism
por: Peana, Alessandra T., et al.
Publicado: (2017)

Atrial fibrillation: A never ending story?
por: Lanters, Eva A. H., et al.
Publicado: (2019)

Cannabinoids in Glaucoma Patients: The Never-Ending Story
por: Passani, Andrea, et al.
Publicado: (2020)

Golden cats: A never‐ending story!
por: Abitbol, Marie, et al.
Publicado: (2022)

Parkinson’s disease: a never ending story
por: Reichmann, Heinz, et al.
Publicado: (2023)

Kawasaki Disease: A Never-ending Story?
por: Lianza, Alessandro Cavalcanti, et al.
Publicado: (2023)

A never-ending FLT3 story
por: Kiyoi, Hitoshi
Publicado: (2023)

Commentary: Never let the truth get in the way of a good story
por: Alsoufi, Bahaaldin
Publicado: (2020)

Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study
por: Guglielmelli, Paola, et al.
Publicado: (2022)

A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis
por: Maffioli, Margherita, et al.
Publicado: (2022)

Rabies in Pakistan: A never ending challenge
por: Kumar, Harendra, et al.
Publicado: (2022)

Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib
por: Abidi, Maheen Z., et al.
Publicado: (2016)

Ruxolitinib therapy for myelofibrosis in Austria: Consensus on therapy management
por: Krauth, Maria-Theresa, et al.
Publicado: (2018)

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
por: Pacilli, Annalisa, et al.
Publicado: (2018)

Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications
por: Ross, David M., et al.
Publicado: (2021)

Real-life ruxolitinib experience in intermediate-risk myelofibrosis
por: Arikan, Fatma, et al.
Publicado: (2021)

Marked Hyperbilirubinemia Associated with Primary Myelofibrosis Responsive to Ruxolitinib
por: Sandhu, Sunny, et al.
Publicado: (2022)

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
por: Verstovsek, Srdan, et al.
Publicado: (2023)

Healthcare-Associated Pneumonia: A Never-Ending Story
por: Russo, Alessandro, et al.
Publicado: (2014)

The relevance of periprocedural troponin rise: the never ending story!
por: Fröhlich, Georg Marcus, et al.
Publicado: (2017)

Colorectal Liver Metastases: A Never Ending Story
por: Lee, Min Ro, et al.
Publicado: (2016)

From sugar to kidney: A never‐ending battle
por: Lin, Yu‐Feng, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_m62mf42his92sfg1t4r2rh24vh